- Home
- GES vs APLT Comparison
GES vs APLT Comparison
Compare GES & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GES
- APLT
- Stock Information
- Founded
- GES 1981
- APLT 2016
- Country
- GES Switzerland
- APLT United States
- Employees
- GES N/A
- APLT N/A
- Industry
- GES Apparel
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- GES Consumer Discretionary
- APLT Health Care
- Exchange
- GES Nasdaq
- APLT Nasdaq
- Market Cap
- GES 547.7M
- APLT 42.5M
- IPO Year
- GES 1996
- APLT 2019
- Fundamental
- Price
- GES $12.46
- APLT $0.32
- Analyst Decision
- GES Buy
- APLT Buy
- Analyst Count
- GES 4
- APLT 7
- Target Price
- GES $17.75
- APLT $6.10
- AVG Volume (30 Days)
- GES 900.8K
- APLT 2.3M
- Earning Date
- GES 06-05-2025
- APLT 08-06-2025
- Dividend Yield
- GES 9.61%
- APLT N/A
- EPS Growth
- GES N/A
- APLT N/A
- EPS
- GES 0.10
- APLT N/A
- Revenue
- GES $3,051,131,000.00
- APLT $265,000.00
- Revenue This Year
- GES $7.34
- APLT $1,768.13
- Revenue Next Year
- GES $3.20
- APLT $292.85
- P/E Ratio
- GES $129.19
- APLT N/A
- Revenue Growth
- GES 9.02
- APLT N/A
- 52 Week Low
- GES $8.48
- APLT $0.30
- 52 Week High
- GES $24.64
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- GES 57.92
- APLT 40.67
- Support Level
- GES $11.80
- APLT $0.30
- Resistance Level
- GES $12.16
- APLT $0.39
- Average True Range (ATR)
- GES 0.42
- APLT 0.03
- MACD
- GES 0.02
- APLT -0.00
- Stochastic Oscillator
- GES 71.53
- APLT 10.00
About GES Guess? Inc.
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.